Senores Pharmaceuticals Ltd IPO
Open Demat Account
Senores Pharmaceuticals Ltd IPO Details
Details
| Total Shares Offered | Offer to Public | Retail Max (Shares) | Pre Issue Promoters Holding | Exchange | Issue size |
|---|---|---|---|---|---|
| ₹ 148.88 L | ₹ 21 L | ₹ 14.81 L | ₹ 221.76 L | BSE | ₹ 582.11 Cr |
| IPO Open Date | Close Date | Lot Size | Min Investment | Issue Type | Listing Date |
| 20 Dec, 24 | 24 Dec, 24 | 38 | ₹ 14,136 | Book Building | 30 Dec, 24 |
Senores Pharmaceuticals Ltd IPO Dates
Details
| Sector | Type |
|---|---|
| Sector | Pharmaceuticals - Indian - Formulations |
| Sub Sector | NA |
| Issue Type | Book Building |
Subscription Status
*Values are in Lakhs
| Investor Type | Subscription Times | Shares Offered* | Shares Bid* |
|---|---|---|---|
| QIB | 39.14x | 11109543 | 434778102 |
| NII | 100.35x | 2221909 | 222963632 |
| Retail | 93.16x | 1481272 | 137996278 |
| Employee | 19.92x | 75000 | 1494122 |
| Total | 53.55x | 14887723 | 797232134 |
Subscription Status
Investor Type
QIB
NII
Retail
Employee
Total
*Values are in Lakhs
Senores Pharmaceuticals Ltd Financial Status
Income Statement
Balance Sheet
| Particulars (in Rs. Crores) | FY23 | FY22 | FY21 |
|---|---|---|---|
| Revenue from operations | 214.52 | 35.34 | 14.17 |
| EBITDA | 6.11 | 3.80 | 2.25 |
| PAT | 0.81 | 1.20 | 0.68 |
| Total Assets | 40.16 | 27.86 | 14.43 |
| Share Capital | 30.51 | 9.82 | 8.74 |
| Total Borrowings | 17.77 | 11.93 | 3.66 |
| Operating Activities (Net Cash) | 2.85 | 2.13 | 1.39 |
| Investing Activities (Net Cash) | 63.11 | -3.10 | 8.52 |
| Financing Activities (Net Cash) | 17.77 | 11.93 | 3.66 |
| Net Cashflow | 10.44 | 0.09 | 1.41 |
Particulars (in Rs. Crores)
Revenue from operations
EBITDA
PAT
Total Assets
Share Capital
Total Borrowings
Operating Activities (Net Cash)
Investing Activities (Net Cash)
Financing Activities (Net Cash)
Net Cashflow
About Senores Pharmaceuticals Ltd
Our Company was originally incorporated as Senores Pharmaceuticals Private Limited a private limited company under the Companies Act, 2013 through a certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. Thereafter, the name of the Company was changed to Senores Pharmaceuticals Limited upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023 and a special resolution passed in the general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.
As per the F&S Report, the US pharmaceutical market increased from USD 589.0 billion in CY 2021 to USD 711.0 billion in CY 2023. The US CDMO market grew from USD 36.3 billion in CY 2021 to USD 44.7 billion in CY 2023. The Emerging pharmaceutical market rose from USD 354.3 billion in CY 2021 to USD 376.3 billion in CY 2023. The Indian hospital channel market expanded from USD 3.9-4.7 billion in CY 2021 to USD 4.7-5.7 billion in CY 2023 while the India API market increased from USD 11.5 billion to USD 13.1 billion in the same period.
We are a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms. Our Regulated Markets business is primarily focused on the Regulated Markets of US, Canada, and United Kingdom. We have adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and as of March 31, 2024, we have received approvals for 19 ANDAs. We develop and manufacture generic pharmaceutical products across various therapeutic areas for the Emerging Markets in the B2B segment, having a presence across 43 countries. We also operate a Critical Care Injectables Business, supplying critical care injectables to hospitals across India through distributors, and manufacture APIs for the domestic market and SAARC countries.
Peer Comparison:
- Ajanta Pharma Ltd
- Alembic Pharmaceuticals Ltd
- Caplin Point Laboratories Ltd
- Gland Pharma Ltd
- Strides Pharma Science Ltd
Senores Pharmaceuticals Ltd IPO Key Points
Strengths
- Ability to cater to the Regulated Markets of US, Canada and the United Kingdom through our US FDA approved formulation manufacturing facility in the US.
- Distinct niche product portfolio built in a short span for Regulated Markets of US, Canada and the United Kingdom.
- Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets, US, Canada and the United Kingdom.
- Presence in the Emerging Markets with a product portfolio, including specialty or complex products.
- R&D capabilities driving our differentiated portfolio of products.
Risk
- The company business is dependent on the sale of its products through third party marketing partners and distributors. The loss of one or more marketing partners or distributors, the deterioration of their financial condition or prospects, or a reduction in their demand for its products or the company inability to maintain and increase the number of its arrangements for the marketing and distribution of the company products could adversely affect its business, results of operations, financial conditions and cash flows.
- The company business is dependent on the sale of its products and continued growth of the Regulated Markets. Decrease in market growth for its product or failures to respond to change in market conditions could adversely affect its business, results of operations, financial conditions and cash flows.
- Failures to comply with the quality standards and technical specifications prescribed by its customers may lead to loss of business from such customers and could negatively impact its business, results of operations and financial condition, including cancellation of existing and future orders which may expose it to warranty claims.
Strategy
- Enhance market presence of our Marketed Products in North America and other Regulated Markets.
- Launch of products in the US with New Drug Applications (NDA) approval.
- Expanding into new Regulated and Emerging Markets.
- Strategic alliance for CMO/ CDMO in Regulated Markets.
- Pursuing an integrated approach to our business by enhancing our capabilities for greater backward integration.
- Ability to cater to the Regulated Markets of US, Canada and the United Kingdom through our US FDA approved formulation manufacturing facility in the US.
- Distinct niche product portfolio built in a short span for Regulated Markets of US, Canada and the United Kingdom.
- Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets, US, Canada and the United Kingdom.
- Presence in the Emerging Markets with a product portfolio, including specialty or complex products.
- R&D capabilities driving our differentiated portfolio of products.
How To Apply for Senores Pharmaceuticals Ltd IPO Online?
Step 1:
Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.
Step 2:
From the list of open IPOs, select the IPO you want to invest.
Step 3:
Go through the IPO details like lot size, price band, about the company, etc.
Step 4:
Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.
Step 5:
Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.
